Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Taplucainium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study
Details : NOC-110 (taplucainium) is a proprietary molecule in the novel class of charged sodium channel blockers, being investigated for the treatment of chronic cough.
Product Name : NOC-110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : Taplucainium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taplucanium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Arkin Bio Ventures
Deal Size : $62.0 million
Deal Type : Series B Financing
Nocion Raises $62M in Series B to Advance Lead Cough Program
Details : The proceeds from the financing will be used to evaluate the lead program, NTX-1175 (taplucanium) dry powder for inhalation. It is being evaluated in Phase II clinical trial studies for Chronic Cough.
Product Name : NTX-1175
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 03, 2024
Lead Product(s) : Taplucanium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Arkin Bio Ventures
Deal Size : $62.0 million
Deal Type : Series B Financing
Lead Product(s) : NTX-1175
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NTX-1175 is being developed to treat cough and has received priority review through the U.K.’s Medicines and Healthcare products Regulatory Agency, as NOC-100 has the potential to treat both chronic and acute cough.
Product Name : NOC-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : NTX-1175
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NTX-1175
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nocion Therapeutics Advances to Clinical Stage and Expands Leadership
Details : First subject in a healthy volunteer Phase 1 trial of NOC-100, an inhaled formulation of NTX-1175. NTX-1175 is a novel small molecule Charged Sodium Channel Blocker (“CSCB”) being developed for cough.
Product Name : NOC-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2020
Lead Product(s) : NTX-1175
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable